pHSA导向α-干扰素制备及其抗肝炎病毒效果研究  

Production of pHSA-Receptor Targeting cc-Interferon (pHSA-IFN ) and Therapeutic Effect on Viral Hepatitis

作　　者：刘明旭[1] 李莉[1] 张新全[1] 张文瑾[1] 蔡光明[1] 魏振满[1] 陈菊梅[1] 

机构地区：[1]中国人民解放军302医院,北京100039

出　　处：《中西医结合肝病杂志》2000年第6期3-4,共2页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：观察多聚人血白蛋白(pHSA)导向α-干扰素(α-IFN)的体内外抗病毒效果。方法:以戊二醛聚合的pHSA作栽体,合成了导向肝脏干扰素(pHSA-IFN)。体外测定其保护肝细胞和非肝细胞抗病毒感染的效果.同时用于慢性病毒性肝炎志愿者的临床治疗。结果:pHSA-IFN对肝细胞的保护活力高出其对非肝细胞的保护活力4～5倍;肝炎病人治疗有效率(HBeAg或HRV-DNA转阴)达60%,高于一般干扰素(30%)。结论:pHSA-IFN确有肝脏导向作用,不会产生免疫排斥,疗效优于普通干扰素。The antiviral activity of polymerized human serum albumin and a-IFN conjugation is observed both in vitro and in vivo. Method: a-IFN was covalently linked with polymerized human serum albumin carrier to obtain liver targeting a-IFN. Its protective effect against virus infection was tested in vitro on liver and non-liver cell, while its therapeutic effect on chronic viral hepatitis was observed on volunteers. Results: The protective effect against virus infection increased 4-5 times after pHSA targeting. pHSA-IFN was prior to common a-IFN with a higher HBeAg and HBV-DNA (or HCV-RNA) disappearance rate (60% to 30%). But no obvious difference existed between therapeutic and contrast group according to statistical analysis. Conclusion: pHSA-IFN can achieve a higher recovery rate in viral hepatitis than non-targeting a-IFN without adverse effect.

关 键 词：Α-干扰素 多聚人血白蛋白 慢性病毒性肝炎 

分 类 号：R512.6[医药卫生—内科学]